References

  1. 1.Krieger JN, et al. NIH consensus definition and classification of prostatitis. JAMA. 1999;282(3):236-237.
  2. 2.Magistro G, et al. Contemporary management of chronic prostatitis/chronic pelvic pain syndrome. Eur Urol. 2016;69(2):286-297.
  3. 3.Franz J, et al. Chronic primary pelvic pain syndrome in men. Dtsch Arztebl Int. 2023;120(29):508-518.
  4. 4.Lai HH, et al. Male chronic pelvic pain: AUA guideline: Part I. Evaluation and management approach. J Urol. 2025;214(2):116-126.
  5. 5.Kravchick S, et al. A simplified algorithm for management of CP/CPPS and associated entities: a summary table for general urologists. Curr Urol. 2026;20(2):69-81.
  6. 6.Krieger JN, et al. Epidemiology of prostatitis. Int J Antimicrob Agents. 2008;31:S85-S90.
  7. 7.Urological Sciences Research Foundation. NIH Chronic Prostatitis Symptom Index. Accessed March 5, 2026. https://www.usrf.org/questionnaires/Prostatitis_NIH_Symptom_Index.html
  8. 8.Prostate.ie. International Prostate Symptom Score (I-PSS). Accessed March 5, 2026. https://prostate.ie/wp-content/uploads/IPSS.pdf
  9. 9.International Index of Erectile Function. Accessed March 5, 2026. https://houstonmensclinic.com/wp-content/uploads/sites/2/2021/12/International-Index-Of-Erectile-Function.pdf
  10. 10.MDCalc. PHQ-9 (Patient Health Questionnaire-9). Accessed March 5, 2026. https://www.mdcalc.com/calc/1725/phq9-patient-health-questionnaire9
  11. 11.Lam JC, et al. Acute and chronic prostatitis. Am Fam Physician. 2024;110(1):45-51.
  12. 12.Bryk DJ, et al. Using the UPOINT system to manage men with chronic pelvic pain syndrome. Arab J Urol. 2021;19(3):387-393.
  13. 13.Thakkinstian A, et al. α-blockers, antibiotics and anti-inflammatories have a role in the management of chronic prostatitis/chronic pelvic pain syndrome. BJU Int. 2012;110(7):1014-1022.
  14. 14.Shoskes DA, et al. Clinical phenotyping in chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis: a management strategy for urologic chronic pelvic pain syndromes. Prostate Cancer Prostatic Dis. 2009;12(2):177-183.
  15. 15.Franco JV, et al. Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome. Cochrane Database Syst Rev. 2019(10):CD012552.
  16. 16.Magri V, et al. Multidisciplinary approach to prostatitis. Arch Ital Urol Androl. 2019;90(4):227-248.
  17. 17.Graziani A, et al. Chronic prostatitis/chronic pain pelvic syndrome and male infertility. Life (Basel). 2023;13(8):1700.
  18. 18.Franco JV, et al. Non-pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome. Cochrane Database Syst Rev. 2018(5):CD012551.
  19. 19.Cao H. Gut microbiome: a novel preventive and therapeutic target for prostatic disease. Front Cell Infect Microbiol. 2024;14:1431088.
  20. 20.Liu BP, et al. Effect of acupuncture on clinical symptoms and laboratory indicators for chronic prostatitis/chronic pelvic pain syndrome. Int Urol Nephrol. 2016;48(12):1977-1991.
  21. 21.Capodice JL, et al. Complementary and alternative medicine for chronic prostatitis/chronic pelvic pain syndrome. Evid Based Complement Alternat Med. 2005;2(4):495-501.
  22. 22.Roberts RO, et al. Prostatitis as a risk factor for prostate cancer. Epidemiology. 2004;15(1):93-99.
  23. 23.Gasperi M, et al. Chronic prostatitis and comorbid non-urological overlapping pain conditions: a co-twin control study. J Psychosom Res. 2017;102:29-33.
  1. 1.Lerner LB, Barry MJ, Das AK, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline. Unabridged. Published 2021; amended 2023. Accessed April 21, 2026. https://www.auanet.org/documents/Guidelines/PDF/2023%20Guidelines/BPH%20Unabridged%2002-20-24%20Final.pdf
  2. 2.Arnold MJ, Gaillardetz A, Ohiokpehai J. Benign prostatic hyperplasia: rapid evidence review. Am Fam Physician. 2023;107(6):613-622.
  3. 3.De Nunzio C, Aronson W, Freedland SJ, et al. The correlation between metabolic syndrome and prostatic diseases. Eur Urol. 2012;61(3):560-570.
  4. 4.Apostolidis A, de Nunzio C, Tubaro A. What determines whether a patient with LUTS seeks treatment? ICI-RS 2011. Neurourol Urodyn. 2012;31(3):365-369.
  5. 5.Cameron AP, Chung DE, Dielubanza EJ, et al. The AUA/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder. J Urol. 2024;212(1):11-20.
  6. 6.Cheng Y, Chen T, Zheng G, et al. Prevalence and trends in overactive bladder among men in the United States, 2005-2020. Sci Rep. 2024;14(1):16284.
  7. 7.Burnett AL, Walker DR, Feng Q, et al. Undertreatment of overactive bladder among men with lower urinary tract symptoms in the United States: a retrospective observational study. Neurourol Urodyn. 2020;39(5):1378-1386.
  8. 8.D’Ancona C, Haylen B, Oelke M, et al. The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction. Neurourol Urodyn. 2019;38(2):433-477.
  9. 9.Wang Y, Li X, Yang H, et al. Predictive factors of incidental prostate cancer in patients undergoing surgery for presumed benign prostatic hyperplasia: an updated systematic review and meta-analysis. Front Oncol. 2025;15:1561675.
  10. 10.Lu Z, Zhang J, Lin S, et al. Associations between overactive bladder and sleep patterns: a cross-sectional study based on 2007-2014 NHANES. BMC Urol. 2023;23(1):184.
  11. 11.Prostate.ie. International Prostate Symptom Score (I-PSS). Accessed March 5, 2026. https://prostate.ie/wp-content/uploads/IPSS.pdf
  12. 12.Bohnen AM, Groeneveld FP, Bosch JL. Serum prostate-specific antigen as a predictor of prostate volume in the community: the Krimpen study. Eur Urol. 2007;51(6):1645-1652, discussion 1652-1653.
  13. 13.Barry MJ, Fowler FJ Jr, Bin L, et al. The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists. J Urol. 1997;157(1):10-14, discussion 14-15.
  14. 14.Suen LKP, Cheng HL, Yeung SKW, et al. Qualitative insights into the experiences of living with moderate-to-severe lower urinary tract symptoms among community-dwelling ageing males. PLoS One. 2017;12(10):e0187085.
  15. 15.Mantica G, Ambrosini F, Drocchi G, et al. Non-surgical management of BPH: an updated review of current literature and state of the art on natural compounds and medical therapy. Arch Ital Urol Androl. 2024;96(4):13098.
  16. 16.Roehrborn CG, Barkin J, Tubaro A, et al. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study. BJU Int. 2014;113(4):623-635.
  17. 17.Staskin D, Owens-Grillo J, Thomas E, et al. Efficacy and safety of vibegron for persistent symptoms of overactive bladder in men being pharmacologically treated for benign prostatic hyperplasia: results from the phase 3 randomized controlled COURAGE Trial. J Urol. 2024;212(2):256-266.
  18. 18.Hamilton RJ, Chavarriaga J, Khurram N, et al. 5-α Reductase inhibitors and prostate cancer mortality. JAMA Netw Open. 2024;7(8):e2430223.
  19. 19.Hagovska M, Svihra J Sr, Macko L, et al. The effect of pelvic floor muscle training in men with benign prostatic hyperplasia and overactive bladder. World J Urol. 2024;42(1):287.
  20. 20.Stewart KL, Lephart ED. Overview of BPH: symptom relief with dietary polyphenols, vitamins and phytochemicals by nutraceutical supplements with implications to the prostate microbiome. Int J Mol Sci. 2023;24(6):5486.
  21. 21.Hueber PA, Zorn KC. Let’s not forget about TUIP: a highly underutilized, minimally-invasive and durable technique for men with <30 g prostates. Can Urol Assoc J. 2015;9(7):255-256.
  22. 22.Shvero A, Calio B, Humphreys MR, et al. HoLEP: the new gold standard for surgical treatment of benign prostatic hyperplasia. Can J Urol. 2021;28:6-10.
  23. 23.Magistro G, Stief CG, Gratzke C. Prostatic urethral lift versus transurethral resection of the prostate (TURP). Curr Urol Rep. 2017;18(10):82.
  24. 24.Amparore D, De Cillis S, Volpi G, et al. First- and second-generation temporary implantable nitinol devices as minimally invasive treatments for BPH-related LUTS: systematic review of the literature. Curr Urol Rep. 2019;20(8):47.
  25. 25.Roehrborn CG, Teplitsky S, Das AK. Aquablation of the prostate: a review and update. Can J Urol. 2019;26(4):20-24.
  26. 26.Zhang TR, Thorogood SL, Sze C, et al. Current practice patterns in the surgical management of benign prostatic hyperplasia. Urology. 2023;175:157-162.
  27. 27.Kumar V, Vineet K, Deb A. TUR syndrome—a report. Urol Case Rep. 2019;26:100982.
  28. 28.Reich O, Gratzke C, Stief CG. Techniques and long-term results of surgical procedures for BPH. Eur Urol. 2006;49(6):970-978, discussion 978.
  29. 29.Abd-El Kader O, Mohy El Den K, El Nashar A, et al. Transurethral incision versus transurethral resection of the prostate in small prostatic adenoma: long-term follow-up. Afr J Urol. 2012;18(1):29-33.
  30. 30.Osborne LA, Reed P. A review of hypnotherapy for overactive bladder. Int J Clin Exp Hypn. 2019;67(3):278-296.
  31. 31.Lerman M, Lerner A, Galle J, et al. Integrated care in a large public system improves benign prostatic hyperplasia management. Urol Pract. 2026;13(1):33-41.
  1. 1.Thirumalai A, Page ST. Male hormonal contraception. Annu Rev Med. 2020;71:17-31.
  2. 2.Richard C, Pourchasse M, Freton L, et al. Male contraception: what do women think? Prog Urol. 2022;32(4):276-283.
  3. 3.Plana O. Male contraception: research, new methods, and implications for marginalized populations. Am J Mens Health. 2017;11(4):1182-1189.
  4. 4.Wu FCW, Lo K. Initiating male contraception methods. Andrology. 2024;12(7):1529-1534.
  5. 5.Arnold JJ, Villanueva D, Puntkattalee MJ. Vasectomy: common questions and answers. Am Fam Physician. 2025;112(3):264-269.
  6. 6.Centers for Disease Control and Prevention, National Center for Health Statistics. Contraceptive use. January 12, 2026. Accessed June 15, 2026. https://www.cdc.gov/nchs/fastats/contraceptive.htm
  7. 7.Centers for Disease Control and Prevention. National Center for Health Statistics. Table. Percentage of men ages 18–49 who ever had a vasectomy, by selected characteristics: United States, 2022–2023. August 28, 2025. Accessed March 1, 2026. https://www.cdc.gov/nchs/data/hestat/hestat108.htm#table
  8. 8.Sharlip ID, Belker AM, Honig S, et al.; American Urological Association. Vasectomy: AUA guideline. J Urol. 2012;188(6):2482-2491.
  9. 9.American Urological Association. Vasectomy: AUA Guideline (2026).Accessed May 14, 2026. https://www.auanet.org/guidelines-and-quality/guidelines/vasectomy-guideline
  10. 10.Velez D, Pagani R, Mima M, et al. Vasectomy: a guidelines-based approach to male surgical contraception. Fertil Steril. 2021;115(6):1365-1368.
  11. 11.Cook LA, Van Vliet HA, Lopez LM, et al. Vasectomy occlusion techniques for male sterilization. Cochrane Database Syst Rev. 2014(3):CD003991.
  12. 12.Zhu EYS, Saba B, Bernstein AP, et al. Providing a post-vasectomy semen analysis cup at the time of vasectomy rather than post-operatively improves compliance. Transl Androl Urol. 2024;13(1):72-79.
  13. 13.Atkinson M, James G, Bond K, et al. Comparison of postal and non-postal post-vasectomy semen sample submission strategies on compliance and failures: an 11-year analysis of the audit database of the Association of Surgeons in Primary Care of the UK. BMJ Sex Reprod Health. 2022;48(1):54-59.
  14. 14.Peacock J, James G, Atkinson M, et al. Complications of vasectomy: results from a prospective audit of 105 393 procedures. BJU Int. 2024;134(5):789-795.
  15. 15.Dubin JM, White J, Ory J, et al. Vasectomy reversal vs. sperm retrieval with in vitro fertilization: a contemporary, comparative analysis. Fertil Steril. 2021;115(6):1377-1383.
  16. 16.Abbe CR, Page ST, Thirumalai A. Male contraception. Yale J Biol Med. 2020;93(4):603-613.
  17. 17.Sanchez NDRR, Ritagliati C, Kopf GS, et al. The uniqueness of on-demand male contraception. Mol Aspects Med. 2024;97:101281.
  18. 18.Brannigan RE, Hermanson L, Kaczmarek J, et al. Updates to male infertility: AUA/ASRM guideline (2024). J Urol. 2024;212(6):789-799.
  19. 19.Fainberg J, Kashanian JA. Recent advances in understanding and managing male infertility. F1000Res. 2019;8:F1000 Faculty Rev-670.
  20. 20.Barratt CLR, Björndahl L, De Jonge CJ, et al. The diagnosis of male infertility: an analysis of the evidence to support the development of global WHO guidance-challenges and future research opportunities. Hum Reprod Update. 2017;23(6):660-680.
  21. 21.Practice Committee of the American Society for Reproductive Medicine. Tobacco or marijuana use and infertility: a committee opinion. Fertil Steril. 2024;121(4):589-603.
  22. 22.Braverman AM, Davoudian T, Levin IK, et al. Depression, anxiety, quality of life, and infertility: a global lens on the last decade of research. Fertil Steril. 2024;121(3):379-383.
  23. 23.Goverde AJ, McDonnell J, Vermeiden JP, et al. Intrauterine insemination or in-vitro fertilisation in idiopathic subfertility and male sub-fertility: a randomised trial and cost-effectiveness analysis. Lancet. 2000;355(9197):13-18.
  24. 24.Chawre S, Khatib MN, Rawekar A, et al. A review of semen analysis: updates from the WHO Sixth Edition Manual and Advances in Male Fertility Assessment. Cureus. 2024;16(6):e63485.
  25. 25.World Health Organization. WHO Laboratory Manual for the Examination and Processing of Human Semen, 6th ed. 2021. Accessed June 16, 2026. https://www.who.int/publications/i/item/9789240030787/
  26. 26.Yu X, Zhang S, Wei Z, et al. Prevalence of sexual dysfunction among the male populations who seeking medical care for infertility, pregnancy loss and preconception care: a cross-sectional study. Sci Rep. 2022;12(1):12969.
  27. 27.Su HI, Lacchetti C, Letourneau J, et al. Fertility preservation in people with cancer: ASCO guideline update. J Clin Oncol. 2025;43(12):1488-1515.
  1. 1.American Cancer Society. Key statistics for prostate cancer. Published January 19, 2024. Accessed May 10, 2026. https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html
  2. 2.American Cancer Society. Cancer statistics center. Published 2024. Accessed May 10, 2026. https://cancerstatisticscenter.cancer.org/?_gl=1
  3. 3.American Cancer Society. Global Cancer Facts & Figures. 5th Edition. Published 2024. Accessed May 10, 2026. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf
  4. 4.James ND, Tannock I, N’Dow J, et al. The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet. 2024;403(10437):1683-1722.
  5. 5.US Preventive Services Task Force. Prostate cancer screening. Published May 8, 2018. Accessed May 10, 2026. https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/prostate-cancer-screening1
  6. 6.Grammatikopoulou MG, Gkiouras K, Papageorgiou ST, et al. Dietary factors and supplements influencing prostate specific-antigen (PSA) concentrations in men with prostate cancer and increased cancer risk: an evidence analysis review based on randomized controlled trials. Nutrients. 2020;12(10):2985.
  7. 7.Lin DW, Carlsson S, Filson CP, et al. Updates to early detection of prostate cancer: AUA/SUO guideline (2026). J Urol. 2026;215(5):491-501.
  8. 8.Kohaar I, Petrovics G, Srivastava S. A rich array of prostate cancer molecular biomarkers: opportunities and challenges. Int J Mol Sci. 2019;20(8):1813.
  9. 9.Matsukawa A, Yanagisawa T, Bekku K, et al. Comparing the performance of digital rectal examination and prostate-specific antigen as a screening test for prostate cancer: a systematic review and meta-analysis. Eur Urol Oncol. 2024;7(4):697-704.
  10. 10.Xu J, McPharlin S, Mulhem E. Prostate cancer screening: common questions and answers. Am Fam Physician. 2024;110(5):493-499.
  11. 11.Franco JV, Hwang EC, Jung JH, et al. Prostate-specific antigen (PSA) test for prostate cancer screening. Cochrane Database Syst Rev. 2026(5):CD004720.
  12. 12.American Academy of Family Physicians. Clinical preventive service recommendation: prostate cancer. Accessed May 10, 2026. https://www.aafp.org/family-physician/patient-care/clinical-recommendations/all-clinical-recommendations/prostate-cancer.html
  13. 13.American Cancer Society. Recommendations for prostate cancer early detection. Accessed May 10, 2026. https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/acs-recommendations.html
  14. 14.Halpern JA, Oromendia C, Shoag JE, et al. Use of digital rectal examination as an adjunct to prostate specific antigen in the detection of clinically significant prostate cancer. J Urol. 2018;199(4):947-953.
  15. 15.Voigt JD, Dong Y, Linder V, et al. Use of the 4Kscore test to predict the risk of aggressive prostate cancer prior to prostate biopsy: overall cost savings and improved quality of care to the US healthcare system. Rev Urol. 2017;19(1):1-10.
  16. 16.Roobol MJ, de Vos II, Månsson M, et al. ERSPC Investigators. European study of prostate cancer screening—23-year follow-up. N Engl J Med. 2025;393(17):1669-1680.
  17. 17.Al Hussein Al Awamlh B, Wallis CJD, Penson DF, et al. Functional outcomes after localized prostate cancer treatment. JAMA. 2024;331(4):302-317.
  18. 18.Huang D, Yang X, Wu Y, et al. Cost-effectiveness analysis of prostate health index in decision making for initial prostate biopsy. Front Oncol. 2020;10:565382.
  19. 19.Fossati N, Buffi NM, Haese A, et al. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and Prostate Health Index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer: results from a multicentric European prospective study. Eur Urol. 2015;68(1):132-138.
  20. 20.Tosoian JJ, Mamawala M, Epstein JI, et al. Active surveillance of grade group 1 prostate cancer: long-term outcomes from a large prospective cohort. Eur Urol. 2020;77(6):675-682.
  21. 21.Gordetsky J, Rais-Bahrami S, Epstein JI. Pathological findings in multiparametric magnetic resonance imaging/ultrasound fusion-guided biopsy: relation to prostate cancer focal therapy. Urology. 2017;105:18-23.
  22. 22.Nedelcu A, Oerther B, Benkendorff A, et al. PI-RADS Version 2.1 for prostate MRI interpretation: associations of study quality and cancer detection metrics—a systematic review and meta-analysis. AJR Am J Roentgenol. 2026;226(2):e2533583.
  23. 23.Frye TP, George AK, Kilchevsky A, et al. Magnetic resonance imaging-transrectal ultrasound guided fusion biopsy to detect progression in patients with existing lesions on active surveillance for low and intermediate risk prostate cancer. J Urol. 2017;197(3):640-646.
  24. 24.Eastham JA, Barocas D, Chu C, et al. Clinically localized prostate cancer: AUA/ASTRO guideline amendment (2026). J Urol. 2026;216(1):2-11.
  25. 25.Buyyounouski MK, Choyke PL, McKenney JK, et al. Prostate cancer—major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(3):245-253.
  26. 26.Srigley JR, Delahunt B, Egevad L, et al. One is the new six: the International Society of Urological Pathology (ISUP) patient-focused approach to Gleason grading. Can Urol Assoc J. 2016;10(9):339-341.
  27. 27.American Urological Association. Advanced prostate cancer AUA/SUO guideline (2026). Accessed May 10, 2026. https://www.auanet.org/guidelines-and-quality/guidelines/advanced-prostate-cancer
  28. 28.National Cancer Institute. Prostate Cancer Treatment (PDQ®)–Health Professional Version. Updated May 14, 2025. Accessed May 10, 2026. https://www.cancer.gov/types/prostate/patient/prostate-treatment-pdq
  29. 29.National Cancer Institute; Surveillance, Epidemiology, and End Results Program. SEER Incidence Data, November 2024 Submission (1975-2022), SEER 21 registries (excluding Illinois). Expected survival life tables by socio-economic standards. Published July 2, 2025. Accessed May 10, 2026. https://seer.cancer.gov/statistics-network/explorer
  30. 30.Coughlin SS. A review of social determinants of prostate cancer risk, stage, and survival. Prostate Int. 2020;8(2):49-54.
  31. 31.Aizer AA, Chen MH, McCarthy EP, et al. Marital status and survival in patients with cancer. J Clin Oncol. 2013;31(31):3869-3876.

Current edition

Common Male Genitourinary Issues

Common Male Genitourinary Issues

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.